Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
North America Canada Market Access

'Status Quo' Interim Pricing Guidance Now In Force In Canada

  • News

Executive Summary

Provisional guidance on controversial pricing reforms is now in place in Canada.

You may also be interested in...



Canada Says Reference Price Changes Could Save Payers Billions

Changes to Canada’s reference pricing system kick in on 1 July and could save billions.

Canada Pulls Controversial Pricing Measures

Some measures aimed at reducing medicine prices in Canada have been dropped, to the relief of the pharmaceutical industry.

Brazilian HTA To Adopt Cost-Effectiveness Thresholds

Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Table

View full table

Topics

Tags:
North America Canada Market Access
Latest News

Amylyx Relyvrio: Pricing, Compounding, And The Shadow Of Makena

Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim

China Drug Price Negotiations: Another Race To The Bottom？

Biogen/Eisai’s Lecanemab Suggests A New Model For Accelerated Approval In The US

See All
UsernamePublicRestriction

Register

PS146906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By